These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Naloxone's dose-dependent displacement of [ Kang Y; O'Conor KA; Kelleher AC; Ramsey J; Bakhoda A; Eisenberg SM; Zhao W; Stodden T; Pearson TD; Guo M; Brown N; Liow JS; Fowler JS; Kim SW; Volkow ND Sci Rep; 2022 Apr; 12(1):6429. PubMed ID: 35440607 [TBL] [Abstract][Full Text] [Related]
4. Total-body imaging of mu-opioid receptors with [ Hsieh CJ; Hou C; Lee H; Tomita C; Schmitz A; Plakas K; Dubroff JG; Mach RH Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3273-3283. PubMed ID: 38722383 [TBL] [Abstract][Full Text] [Related]
5. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level. Moss RB; Pryor MM; Baillie R; Kudrycki K; Friedrich C; Reed M; Carlo DJ PLoS One; 2020; 15(6):e0234683. PubMed ID: 32544184 [TBL] [Abstract][Full Text] [Related]
6. Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest. Laffont CM; Purohit P; Delcamp N; Gonzalez-Garcia I; Skolnick P Front Psychiatry; 2024; 15():1399803. PubMed ID: 38952632 [TBL] [Abstract][Full Text] [Related]
7. Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. Johansson J; Hirvonen J; Lovró Z; Ekblad L; Kaasinen V; Rajasilta O; Helin S; Tuisku J; Sirén S; Pennanen M; Agrawal A; Crystal R; Vainio PJ; Alho H; Scheinin M Neuropsychopharmacology; 2019 Aug; 44(9):1667-1673. PubMed ID: 30867551 [TBL] [Abstract][Full Text] [Related]
8. Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest. Mann J; Samieegohar M; Chaturbedi A; Zirkle J; Han X; Ahmadi SF; Eshleman A; Janowsky A; Wolfrum K; Swanson T; Bloom S; Dahan A; Olofsen E; Florian J; Strauss DG; Li Z Clin Pharmacol Ther; 2022 Nov; 112(5):1020-1032. PubMed ID: 35766413 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity. Baehr CA; Wu MM; Pandit SG; Arias-Umana J; AuCoin D; Pravetoni M J Pharmacol Exp Ther; 2022 May; 381(2):129-136. PubMed ID: 35153198 [TBL] [Abstract][Full Text] [Related]
10. Preparation and biodistribution in mice of [11C]carfentanil: a radiopharmaceutical for studying brain mu-opioid receptors by positron emission tomography. Saji H; Tsutsumi D; Magata Y; Iida Y; Konishi J; Yokoyama A Ann Nucl Med; 1992 Feb; 6(1):63-7. PubMed ID: 1325823 [TBL] [Abstract][Full Text] [Related]
11. Comparison of [11C]diprenorphine and [11C]carfentanil in vivo binding to opiate receptors in man using a dual detector system. Villemagne VL; Frost JJ; Dannals RF; Lever JR; Tanada S; Natarajan TK; Wilson AA; Ravert HT; Wagner HN Eur J Pharmacol; 1994 May; 257(1-2):195-7. PubMed ID: 7915990 [TBL] [Abstract][Full Text] [Related]
12. Synthetic opioids have disrupted conventional wisdom for treating opioid overdose. Skolnick P; Paavola J; Heidbreder C Drug Alcohol Depend Rep; 2024 Sep; 12():100268. PubMed ID: 39262668 [TBL] [Abstract][Full Text] [Related]
13. Mu opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain. Titeler M; Lyon RA; Kuhar MJ; Frost JF; Dannals RF; Leonhardt S; Bullock A; Rydelek LT; Price DL; Struble RG Eur J Pharmacol; 1989 Aug; 167(2):221-8. PubMed ID: 2556284 [TBL] [Abstract][Full Text] [Related]
14. In vivo binding of [125I]NH2-carfentanil to mu opioid receptors in mouse brain. Tafani JA; Francés B; Coulais Y; Méjean-Galzi A; Goeldner M; Hirth C; Guiraud R; Zajac JM Nucl Med Biol; 1994 Feb; 21(2):231-8. PubMed ID: 9234287 [TBL] [Abstract][Full Text] [Related]
15. High-dose naloxone formulations are not as essential as we thought. Lemen PM; Garrett DP; Thompson E; Aho M; Vasquez C; Park JN Harm Reduct J; 2024 May; 21(1):93. PubMed ID: 38741224 [TBL] [Abstract][Full Text] [Related]
16. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. Pergolizzi JV; Dahan A; Ann LeQuang J; Raffa RB J Clin Pharm Ther; 2021 Dec; 46(6):1501-1504. PubMed ID: 34111307 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the rate of reversal of fentanyl-induced respiratory depression using a novel long-acting naloxone nanoparticle, cNLX-NP. Averick SE; Kassick AJ; Song D; Zhang B; Vigliaturo J; Luengas D; Silva-Ortiz P; Pravetoni M; Raleigh MD Front Psychiatry; 2024; 15():1366186. PubMed ID: 38550534 [TBL] [Abstract][Full Text] [Related]
18. The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects. Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME Alcohol; 2012 Sep; 46(6):511-7. PubMed ID: 22717196 [TBL] [Abstract][Full Text] [Related]
19. [11C]Carfentanil Binds Preferentially to μ-Opioid Receptor Subtype 1 Compared to Subtype 2. Eriksson O; Antoni G Mol Imaging; 2015; 14():476-83. PubMed ID: 26461068 [TBL] [Abstract][Full Text] [Related]
20. Carfentanil toxicity in the African green monkey: Therapeutic efficacy of naloxone. Langston JL; Moffett MC; Makar JR; Burgan BM; Myers TM Toxicol Lett; 2020 Jun; 325():34-42. PubMed ID: 32070766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]